GI Oncology Now

💉PDR001 is an anti-PD-1 antibody used in immunotherapy across various tumor types. 👉 A recent phase 1B/2 study investigated the safety and efficacy of PDR001 in combination with #imatinib for patients with treatment-refractory gastrointestinal stromal tumors:

⭐ Can a new coupled CAR-T therapy aid patients with metastatic colorectal cancer? 🧪 Dr. Benjamin Schlechter of Dana-Farber Cancer Institute discusses the phase 1 dose escalation study examining GCC19CART and its effects: https://buff.ly/4cX6OY1

🏥 While low anterior resection offers benefits for patients with rectal cancer, many suffer from impaired bowel function after the procedure. 🔬 A new sub-analysis of the FORCE trial sought to determine the effect of early stoma closure on bowel function in patients who underwent LAR:

📺 Dr. Nataliya Uboha spoke with Dr. Thomas Karasic of UW School of Medicine and Public Health on the CCR8 protein found in immune cells in the tumor mircoenvironment and how a new approach can treat gastric cancer using a CCR8-targeting antibody: https://buff.ly/3W7ZlPk

🔎 Watch-and-wait (WW) strategies can help maintain quality of life and avoid potential unnecessary surgical interventions. 🔬 The phase 2 TORCH trial analyzed whether integrating PD-1 inhibitors with total neoadjuvant therapy could improve CR rates and work in conjunction with a WW strategy in patients with pMMR/MSS locally advanced rectal cancer:

❓ Did you know that retinoids can have chemotherapeutic effects on colorectal cancer? 📋 New research has examined the efficacy of targeted therapy using the retinoid #bexarotene for the biomarker SEZ6L2 in patients with colorectal cancer:

❗️Drs. Suneel Kamath, Arvind Dasari, and Sakti Chakrabarti discuss the management of oligometastatic #colorectal cancer in a roundtable moderated by Dr. Shikha Jain: https://buff.ly/4eNZ9No 👉 The panel emphasizes the importance of a multidisciplinary approach, local therapies, and tailored treatments.

💉 A real-world analysis of the phase 3 TOPAZ-1 study conducted by Margherita Rimini, MD, and colleagues found that #gemcitabine plus #cisplatin and #durvalumab shows potential as a first-line treatment for advanced biliary tract cancer. Learn more:

❗️ Dr. Richard Finn of UCLA Health gives an update on the 3-year follow-up data from KEYNOTE-966. 💊 The study assessed pembrolizumab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer: https://buff.ly/4eZjv6K

🔎 A recent study by Dr. Saneya Pandrowala and colleagues has found that a higher burden of liver disease is associated with shorter PFS in patients with metastatic grade I GEP-NETs. 👉 Learn more about the study that determined the factors that influence survival outcomes in patients with GEP-NETs: